---
title: "LifeSci Capital Sticks to Their Buy Rating for Janux Therapeutics Inc (JANX)"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/268835328.md"
description: "LifeSci Capital's Oliver McCammon maintains a Buy rating for Janux Therapeutics Inc with a $60 price target. McCammon, who covers the Healthcare sector, has an average return of 114.4% and a 53.13% success rate. Clear Street's Kaveri Pohlman also issued a Buy rating, while TR | OpenAI – 4o reiterated a Hold rating. The report highlights TipRanks' Cyber Monday sale offering 60% off Premium subscriptions."
datetime: "2025-12-06T15:35:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/268835328.md)
  - [en](https://longbridge.com/en/news/268835328.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/268835328.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/268835328.md) | [繁體中文](https://longbridge.com/zh-HK/news/268835328.md)


# LifeSci Capital Sticks to Their Buy Rating for Janux Therapeutics Inc (JANX)

In a report released today, Oliver McCammon from LifeSci Capital maintained a Buy rating on Janux Therapeutics Inc, with a price target of $60.00.

### TipRanks Cyber Monday Sale

-   Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
-   Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off

McCammon covers the Healthcare sector, focusing on stocks such as Janux Therapeutics Inc, Perspective Therapeutics, and Corbus Pharmaceuticals. According to TipRanks, McCammon has an average return of 114.4% and a 53.13% success rate on recommended stocks.

In addition to LifeSci Capital, Janux Therapeutics Inc also received a Buy from Clear Street’s Kaveri Pohlman in a report issued on December 2. However, on December 3, TR | OpenAI – 4o reiterated a Hold rating on Janux Therapeutics Inc (NASDAQ: JANX).

### 相关股票

- [Janux Therapeutics (JANX.US)](https://longbridge.com/zh-CN/quote/JANX.US.md)

## 相关资讯与研究

- [OpenAI is now bringing in $2 billion a month - and 3 more highlights from its latest update](https://longbridge.com/zh-CN/news/281258023.md)
- [OpenAI's ad push explained in one chart](https://longbridge.com/zh-CN/news/281235106.md)
- [LifeSci Capital Keeps Their Buy Rating on Enliven Therapeutics (ELVN)](https://longbridge.com/zh-CN/news/280882703.md)
- [Pyxis Oncology (PYXS) Receives a Rating Update from a Top Analyst](https://longbridge.com/zh-CN/news/280883162.md)
- [OpenAI, not yet public, raises $3B from retail investors in monster $122B fund raise](https://longbridge.com/zh-CN/news/281250634.md)